Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial

Abstract

Schizophrenic patients have a high rate of smoking and cognitive deficits which may be related to a decreased number or responsiveness of nicotinic receptors in their brains. Varenicline is a partial nicotinic agonist which is effective as an antismoking drug in cigarette smokers, although concerns have been raised about potential psychiatric side-effects. We conducted a double-blind placebo controlled study in 87 schizophrenic smokers to evaluate the effects of varenicline (2 mg/day) on measures of smoking, cognition, psychiatric symptoms, and side-effects in schizophrenic patients who were cigarette smokers. Varenicline significantly decreased cotinine levels (P<0.001), and other objective and subjective measures of smoking (P < .01), and responses on a smoking urges scale (P = .02), more than placebo. Varenicline did not improve scores on a cognitive battery designed to test the effect of drugs on cognitive performance in schizophrenia (the MATRICS battery), either in overall MATRICS battery Composite or individual Domain scores, more than placebo. There were no significant differences between varenicline vs. placebo effects on total symptom scores on psychiatric rating scales, PANSS, SANS, or Calgary Depression scales, and there were no significant drug effects in any of these scales sub-scores when we used Benjamin-Hochberg corrected significance levels (α = .05). Varenicline patients did not show greater side-effects than placebo treated patients at any time point when controlled for baseline side-effect scores. Our study supports the use of varenicline as a safe drug for smoking reduction in schizophrenia but not as a cognitive enhancer.Trial Registration: ClinicalTrials.gov 00802919

The effects of nicotine in the neonatal quinpirole rodent model of psychosis: Neural plasticity mechanisms and nicotinic receptor changes

“…Interestingly, the common smoking cessation treatment, varenicline (Trade name: Chantix), which is a partial agonist at the α4β2 nAChR, has been generally shown to be effective for smoking cessation in populations diagnosed with psychosis [44], and the more robust upregulation of α4β2 nAChR density in NQ animals observed in the present study is consistent with this outcome. Past work has shown that there is a complex interaction between dopamine D 2 receptors and α4β2 nAChRs in the striatum, with α4 nAChRs and dopamine D 2 receptors both co-localized on cholinergic interneurons.…”

Effects of transcranial direct current stimulation (tDCS) on cognition, symptoms, and smoking in schizophrenia: A randomized controlled study

“…It is possible that SZ who were more committed to smoking cessation or reduction, or were very heavy smokers, might have shown stronger effects. However, in other studies we have conducted in similar groups of SZ smokers who were not committed to smoking cessation, using the anti-smoking drug varenicline, we showed reduction in a craving measure (QSU), number of cigarettes smoked, and Breathalyzer CO (Smith et al, 2009(Smith et al, , 2013. The lack of differential craving induced by a standard set of cigarette craving slides, compared to neutral slides, in this population was unexpected.…”

Pharmacological enrichment of polygenic risk for precision medicine in complex disorders

“…This accorded with previous reports in the literature of schizophrenia associated common variant enrichment in the targets of antiepileptics 14 . Some interesting repurposing candidates with previous clinical trials in the disorder included the psychostimulant Atomoxiene 15 , which targets the NOS1 pathway, the α4β2 nicotinic acetylcholine receptor subtype partial agonist Varenicline 16 , and ascorbic acid (Vitamin C) 17 . Whilst the results of these trials were mixed, targeting such interventions to specific individuals based on genomic risk is yet to be investigated.…”